In August, 2017, CF PharmTech, Inc. successfully completed the D-round financing of RMB 440 million. This round of financing is led by the advanced manufacturing industry investment fund managed by SDIC Innovation Investment Management Co., Ltd. and jointly funded by new and old investors such as CCB International, Qianhai Yuanming, Longmen Investment and Hengyu Tianze. This round of financing is one of the largest financing projects of pharmaceutical start-ups in China so far in 2017.

Founded by a team of scientists and entrepreneurs studying in the United States, CF PharmTech, Inc. is committed to providing all-round high-quality inhalation preparations for domestic patients, and actively participating in the high-level competition of inhalation preparations in the European and American markets. Since its establishment, the company has focused on the technical development and product development of aerosol, dry powder, nasal spray and atomizer, and has established a research and development platform and production facilities involving these dosage forms. This kind of dosage form has high technical threshold and complex production process, and there are only a few enterprises devoted to the development of this kind of dosage form all over the world. Since its establishment, the company has successively obtained the support of domestic industrial funds and famous investment institutions such as Shuanglu Pharmaceutical, Sihong Investment, Galaxy Investment, Kaifeng Venture Capital, Jinfeng Lingheng, Zhongxin Venture Capital, Wuhu Ruiye, Jinpu Health, etc.

The project team entrusted to provide full legal services for the project includes AllBright Senior Partner Carl Li and Partner Summer Sheng.